Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
(UroToday.com) The 2026 American Society of Clinical Oncology Genitourinary (ASCO) Annual Meeting held in Chicago, IL, was host to the Prostate, Testicular, and Penile Cancer - Rapid Oral Abstracts ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
ASCO 2024 Bladder Cancer ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options? ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive ...
Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC) - Beyond the Abstract July 14, 2026 AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict ...
(UroToday.com) The 2025 SUO annual meeting featured a kidney session and a presentation by Dr. Brian Shuch discussing ZIRCON-X and the impact of 89 Zr-girentuximab PET/CT versus conventional imaging ...
(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical trial updates session and presentation by Dr. Désirée Deandreis discussing the PEACE-6 PR trial. Recently, prostate cancer is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results